NO20044954L - Bazedoxifen behandlingsregimer - Google Patents

Bazedoxifen behandlingsregimer

Info

Publication number
NO20044954L
NO20044954L NO20044954A NO20044954A NO20044954L NO 20044954 L NO20044954 L NO 20044954L NO 20044954 A NO20044954 A NO 20044954A NO 20044954 A NO20044954 A NO 20044954A NO 20044954 L NO20044954 L NO 20044954L
Authority
NO
Norway
Prior art keywords
bazedoxifene
treatment regimens
azepan
indol
hydroxyphenyl
Prior art date
Application number
NO20044954A
Other languages
English (en)
Norwegian (no)
Inventor
Barry Samuel Komm
Mark A Collins
Wendy Ann Dulin
James C Ermer
Geraldine M Ferron
Pol Boudes
Simon N Jenkins
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20044954L publication Critical patent/NO20044954L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
NO20044954A 2002-06-13 2004-11-12 Bazedoxifen behandlingsregimer NO20044954L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38859602P 2002-06-13 2002-06-13
PCT/US2003/019011 WO2003105834A1 (en) 2002-06-13 2003-06-13 Bazedoxifene treatment regimens

Publications (1)

Publication Number Publication Date
NO20044954L true NO20044954L (no) 2004-12-16

Family

ID=29736501

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044954A NO20044954L (no) 2002-06-13 2004-11-12 Bazedoxifen behandlingsregimer

Country Status (20)

Country Link
US (1) US20040063692A1 (ja)
EP (1) EP1531807A4 (ja)
JP (1) JP2005531613A (ja)
KR (1) KR20050010886A (ja)
CN (1) CN1658868A (ja)
AU (1) AU2003248707A1 (ja)
BR (1) BR0311774A (ja)
CA (1) CA2489098A1 (ja)
CR (1) CR7585A (ja)
EC (1) ECSP045492A (ja)
IL (1) IL165210A0 (ja)
MX (1) MXPA04011634A (ja)
NI (1) NI200400065A (ja)
NO (1) NO20044954L (ja)
NZ (1) NZ537051A (ja)
RU (1) RU2355397C2 (ja)
SG (1) SG162615A1 (ja)
UA (1) UA85374C2 (ja)
WO (1) WO2003105834A1 (ja)
ZA (1) ZA200409991B (ja)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060127875A (ko) * 2004-01-13 2006-12-13 와이어쓰 아로마타제 억제제 요법-관련된 골다공증의 치료
PA8629301A1 (es) * 2004-04-08 2006-10-13 Wyeth Corp Formulaciones de acetato de bezedoxifeno
CA2561004A1 (en) * 2004-04-08 2005-10-27 Wyeth Bazedoxifene ascorbate as selective estrogen receptor modulator
DE602006010343D1 (de) * 2005-03-31 2009-12-24 Wyeth Corp Kombinationsprodukt aus o-desmethylvenlafaxin und bazedoxifen und verwendungen davon
JP2008545012A (ja) * 2005-06-29 2008-12-11 ワイス 結合型エストロゲンおよびバゼドキシフェンの医薬処方
PE20070425A1 (es) * 2005-08-24 2007-07-02 Wyeth Corp Composicion farmaceutica que comprende acido 1-[4-(2-azepan-1-il-etoxi)-bencil]-2-(4-hidroxifenil)-3-metil-1h-indol-5-ol acetico (acetato de bazedoxifeno) como modulador selectivo del receptor de estrogenos
CN101541326A (zh) * 2006-11-29 2009-09-23 惠氏公司 雌激素/选择性雌激素受体调节剂（serm）和雌激素/孕酮双层药片
ITMI20091109A1 (it) 2009-06-23 2010-12-24 Wyeth Corp Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione
WO2013182169A1 (en) * 2012-06-07 2013-12-12 Zentiva, K. S. Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate
KR101940569B1 (ko) * 2017-05-24 2019-01-21 아주대학교산학협력단 바제독시펜 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물
CN112076163B (zh) * 2019-06-14 2023-06-20 四川科伦药物研究院有限公司 一种醋酸巴多昔芬片的药物组合物及其制备方法
CN113244240A (zh) * 2021-05-26 2021-08-13 深圳市人民医院 醋酸巴多昔芬在治疗急性髓系白血病药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW303299B (ja) * 1993-07-22 1997-04-21 Lilly Co Eli
ES2162198T3 (es) * 1996-04-19 2001-12-16 American Home Prod Agentes estrogenos.
US5998402A (en) * 1996-04-19 1999-12-07 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
US6479535B1 (en) * 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
US6583170B1 (en) * 1998-05-15 2003-06-24 Wyeth 2-Phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol and estrogen formulations
WO2002003992A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003991A2 (en) * 2000-07-06 2002-01-17 Wyeth Use of substituted indole compounds for increasing nitric oxide synthase activity
AR029538A1 (es) * 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
EP1192945A3 (en) * 2000-09-21 2004-03-03 Pfizer Products Inc. Use of an estrogen agonist/antagonist for treating osteoarthritis

Also Published As

Publication number Publication date
RU2355397C2 (ru) 2009-05-20
NZ537051A (en) 2007-11-30
AU2003248707A1 (en) 2003-12-31
WO2003105834A1 (en) 2003-12-24
KR20050010886A (ko) 2005-01-28
MXPA04011634A (es) 2005-07-05
IL165210A0 (en) 2005-12-18
UA85374C2 (en) 2009-01-26
ZA200409991B (en) 2007-09-26
CR7585A (es) 2008-10-03
NI200400065A (es) 2005-08-09
ECSP045492A (es) 2005-03-10
US20040063692A1 (en) 2004-04-01
EP1531807A1 (en) 2005-05-25
CA2489098A1 (en) 2003-12-24
JP2005531613A (ja) 2005-10-20
EP1531807A4 (en) 2007-10-31
SG162615A1 (en) 2010-07-29
RU2004136316A (ru) 2005-05-10
BR0311774A (pt) 2007-05-08
CN1658868A (zh) 2005-08-24

Similar Documents

Publication Publication Date Title
NO20044954L (no) Bazedoxifen behandlingsregimer
EA200301213A1 (ru) Лиганды рецепторов 5-ht и их применение
NO20052198D0 (no) Enkeltkjedede, rekombinante T-cellereseptorer
EA200500520A1 (ru) Пуриновые соединения и их применение в качестве лигандов каннабиноидных рецепторов
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
DE602005015962D1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE388937T1 (de) Agonisten des cannabinoidrezeptors
IS7607A (is) Ný útskipt indól
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
DE60320439D1 (de) Indolderivate als beta-2 agonisten
NO20053101L (no) Kimaere og humaniserte antistoffer motalfa-5beta-1 integrin som modulerer angiogenese.
NL1026959A1 (nl) Benzimidazolonverbindingen met 5-HT4 receptor agonistische werking.
NO20051042L (no) Pyrimidylsulfonamidderivater som kemokinreseptormodulatorer
DK1505974T3 (da) Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
DE602004015451D1 (de) Sulphonamidverbindungen, die die chemokinrezeptoraktivität (ccr4) modulieren
DK1557411T3 (da) N-phenyl-(2r,5s)-dimethylpiperazin-derivat
DK1637527T3 (da) Cannabinoid receptor modulator.
AR048394A1 (es) Tratamiento de la osteoporosis relacionada con la terapia de inhibidor de aromatasa
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
ATE478845T1 (de) Pyrrolidiniumderivative als liganden für den muscarinen m3-rezeptor
NO20034130L (no) Benzimidazolderivater som modulerer kjemokinreseptor
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
FR2886140B1 (fr) Composition pour la teinture des fibes keratiniques comprenant un derive de diamino-n,n-dihydro-pyrazolone et un derive de l'indole ou de l'indoline
DE60316180D1 (de) Aminoalkoxyindol-derivate als 5-ht6-rezeptorliganden zur bekämpfung von zns-krankheiten
DK1494650T3 (da) Farmaceutisk formulering, der indeholder melatonin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application